Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in a Child with Myelodysplastic Neoplasm with Complex Karyotype and ETV6 Variant: Challenges in Treatment
Authors:
- Elaiza Almeida Antônio de KósEKElaiza Almeida Antônio de Kós
- Viviane Lamim LovatelVLViviane Lamim Lovatel
- Rita de Cássia Barbosa TavaresRTRita de Cássia Barbosa Tavares
- Gerson Moura FerreiraGFGerson Moura Ferreira
- Ana Paula Silva BuenoABAna Paula Silva Bueno
- Elaine Sobral da CostaECElaine Sobral da Costa
- Teresa de Souza FernandezTFTeresa de Souza Fernandez
Open Access
- 1 January 2024
- journal article
- letter
- Published by Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy in Mediterranean Journal of Hematology and Infectious Diseases
- Vol. 16 (1) , e2024040
Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment with the potential for cure in patients with myelodysplastic neoplasm (MDS). Nevertheless, disease relapse is the main cause of treatment failure. Due to the rarity of childhood MDS (cMDS), there are few studies showing the impact of cytogenetic alterations and genetic variants on outcomes of allo-HSCT, mainly focusing on clonal chromosomal evolution (CCE) during relapse post-transplant. Here, we describe a 3-year-old boy with cMDS-IB, who evolved to MDS/AML. At diagnosis, the patient showed a complex karyotype with chromosomal abnormalities not yet reported together in the same clone, and likely a pathogenic variant in the ETV6 gene. The patient was treated with HLA-matched sibling HSCT, but unfortunately relapsed after HSCT with clonal cytogenetic evolution. This unfavorable outcome suggests that the treatment of pediatric MDS associated with predictive factors of poor prognosis, such as complex karyotype and ETV6 variant remains a challenge.Keywords
This publication has 12 references indexed in Scilit:
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic NeoplasmsLeukemia, 2022
- 3q21 deletion affects GATA2 and is associated with myelodysplastic syndromeBritish Journal of Haematology, 2021
- Gene correlation network analysis to identify regulatory factors in sepsisJournal of Translational Medicine, 2020
- How I treat myelodysplastic syndromes of childhoodBlood, 2018
- Cytogenetic Evolution in Myeloid Neoplasms at Relapse after Allogeneic Hematopoietic Cell Transplantation: Association with Previous Chemotherapy and Effect on SurvivalTransplantation and Cellular Therapy, 2017
- ETV6 in hematopoiesis and leukemia predispositionSeminars in Hematology, 2017
- Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panelBlood, 2017
- Atlas of Genetics and Cytogenetics in Oncology and Haematology in 2013Nucleic Acids Research, 2012
- Clinical Effect of Point Mutations in Myelodysplastic SyndromesNew England Journal of Medicine, 2011
- Advances in the prognostication and management of advanced MDS in childrenBritish Journal of Haematology, 2011